Tarsier Pharma is pioneering a bio-inspired therapeutic platform centered around Dazdotuftide (TRS), a novel immunomodulatory compound designed to address autoimmune and inflammatory ocular diseases. This innovative approach aims to control inflammation by targeting the immune system more comprehensively than traditional treatments, which often focus on individual receptors or proteins. Dazdotuftide operates through a dual-target mechanism, inhibiting the Nf-kB signaling pathway and promoting a shift from pro-inflammatory (M1) to anti-inflammatory (M2) macrophages. This mechanism not only aims to effectively manage ocular inflammation but also seeks to minimize the adverse side effects commonly associated with long-term steroid use, such as glaucoma and cataract formation.

The company’s pipeline includes clinical development for conditions like non-infectious anterior uveitis and uveitic glaucoma, which pose significant risks of vision loss. Tarsier Pharma's focus on Dazdotuftide reflects a commitment to providing safe and effective alternatives to corticosteroids, which have been the standard treatment for over 70 years. The promising results from initial clinical trials indicate that Dazdotuftide could offer a compelling risk-benefit profile, potentially reshaping the treatment landscape for ocular inflammatory diseases and improving the quality of life for patients suffering from these debilitating conditions.

Israel

Tarsier® Pharma is a clinical late stage company developing novel treatments for ocular inflammatory blinding diseases, beginning with uveitis.

Tarsier Pharma

Company Details